Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19: How Staff At Belgium’s Medicines Agency Dealt With The Challenges – And The Stress

Executive Summary

Just what was happening behind the scenes at EU regulatory agencies in 2020 as the SARS CoV-2 virus took hold and began its relentless spread? The Belgian agency, the FAMHP, interviewed some of its staff to find out what their experiences were during the early stages of the pandemic, the impact it had on them, and the lessons they learned.

You may also be interested in...



Countries To Discuss Pandemic Treaty Next Year Amid Industry Concern

A World Health Organization negotiating body has agreed to develop a “zero draft” of the proposed pandemic treaty for discussion at a meeting of WHO member states in February next year. But the international pharmaceutical industry has reiterated its concerns about some of the proposals being put forward.

EU Health Ministers Want Changes to COVID-19 Vaccine Contracts Amid Oversupply Concerns

EU member states are calling for a formal approach to making vaccine procurement agreements more flexible, saying that any further delay will “undermine the trust of society in vaccination and vaccines.”

Novel Vaccines Among Wide-Ranging EU Plans To Boost Health Threat Preparedness

Two documents published by the European Commission outline proposals to prepare for future health emergencies such as pandemics and the impact of antimicrobial resistance, with next-generation vaccines and novel or repurposed therapeutics high on the agenda.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel